SO is it correct to say that not much is different? split went from 50/50 to a smaller share for affy?
which was assumed considering that Takeda is funding the recall and investigation. And Affy still holds the patent correct? If a am understanding this right we are in damn good shape. So pleas fill me in if i Misunderstood.
affy shareholders are screwed here. Takeda holds all the cards. Eventually Affy will have zero cash-and will have to declare bankruptcy. Shareholders get nothing. Takeda sits on the drug till that happens
I think you are right on the money. The split went down but Affy also get an additional $180 million in milestones. But the big deal is that all responsibilities for investigation plus post market cost are all on Takeda. This to be is a very lop sided deal in favor of Affy.